CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 52 enrolled
Drug / intervention
IMC-CS4biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01346358
NCT01346358Phase 1Completed
CompareCT.gov

Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available

Eli Lilly and Company·interventional·Posted May 3, 2011·Updated Sep 19, 2024

In Brief

A Phase 1 clinical trial evaluating IMC-CS4 for Neoplasms. Completed, enrolled 52 participants across 6 sites.

Detailed Summary

A dose escalation study to establish the safety profile and characterize the pharmacokinetic profile of IMC-CS4 in the treatment of subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 3, 2011
Enrollment StartJun 15, 2011
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 15.2 years ago

Interventions

IMC-CS4biological